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Abstract
Antiviral monoclonal antibodies (mAbs) represent promising therapeutics. However, most mAbs-based immunotherapies
conducted so far have only considered the blunting of viral propagation and not other possible therapeutic effects
independent of virus neutralization, namely the modulation of the endogenous immune response. As induction of long-
term antiviral immunity still remains a paramount challenge for treating chronic infections, we have asked here whether
neutralizing mAbs can, in addition to blunting viral propagation, exert immunomodulatory effects with protective
outcomes. Supporting this idea, we report here that mice infected with the FrCas
E murine retrovirus on day 8 after birth die
of leukemia within 4–5 months and mount a non-protective immune response, whereas those rapidly subjected to short
immunotherapy with a neutralizing mAb survive healthy and mount a long-lasting protective antiviral immunity with strong
humoral and cellular immune responses. Interestingly, the administered mAb mediates lysis of infected cells through an
antibody-dependent cell cytotoxicity (ADCC) mechanism. In addition, it forms immune complexes (ICs) with infected cells
that enhance antiviral CTL responses through FccR-mediated binding to dendritic cells (DCs). Importantly, the endogenous
antiviral antibodies generated in mAb-treated mice also display the same properties, allowing containment of viral
propagation and enhancement of memory cellular responses after disappearance of the administered mAb. Thus, our data
demonstrate that neutralizing antiviral mAbs can act as immunomodulatory agents capable of stimulating a protective
immunity lasting long after the end of the treatment. They also show an important role of infected-cells/antibody
complexes in the induction and the maintenance of protective immunity through enhancement of both primary and
memory antiviral T-cell responses. They also indicate that targeting infected cells, and not just viruses, by antibodies can be
crucial for elicitation of efficient, long-lasting antiviral T-cell responses. This must be considered when designing antiviral
mAb-based immunotherapies.
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Introduction
Monoclonal antibodies (mAbs) constitute the largest class of
biomedical proteins [1]. They are increasingly being considered as
therapeutic agents to fight both acute and chronic severe human
viral diseases, with many of them developed in the most recent
period [1,2]. Non exclusively, one can cite neutralizing mAbs
against Ebola- [3], West Nile (WNV)- [4], cytomegalo (CMV)- [5],
avian H5N1- [6] and human influenza- [6,7], severe acute
respiratory syndrome (SARS)- [8], respiratory syncytial (RSV)-
[9], hepatitis B (HBV)- [10], hepatitis C (HCV)- [11] and human
immunodeficiency virus (HIV) [1,12] that have shown antiviral
activity in preclinical studies. One of these (Pavilizumab), directed
against RSV, is commercially available, whereas others (see [2] for
more information and references) are currently being tested in
clinical studies for treating either acute cytopathic infections
by WNV and CMV or severe chronic infections by HBV, HCV
and HIV, which figure amongst the heaviest health burdens
worldwide.
Most antiviral mAb-based treatments conducted so far, whether
in humans or in animal models, have only considered the blunting
of viral propagation through direct virus neutralization. However,
mAbs might also operate via complementary mechanisms owing
to their ability to interact with various components of the immune
system via the effector functions borne by their constant regions.
For example, certain viral antigens expressed at the surface of
infected cells, such as envelope glycoproteins (Env) of immunode-
ficiency-inducing viruses, like HIV, or of cancer-inducing viruses,
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target virus reservoirs via complement-dependent- (CDC) or
antibody-dependent cell cytotoxicity (ADCC) mediated by natural
killer cells. Moreover, mAbs form immune complexes (ICs) with
viral antigens exposed at the surface of virions as well as on that of
infected cells for certain viruses. As uptake, processing and MHC
presentation of antigens by antigen-presenting cells (APCs) are
significantly different depending on whether they are complexed
or not to antibody, this may ultimately impact on endogenous
immunity [13,14]. There are several reasons why such alternative
modes of action of mAbs have been poorly investigated in vivo to
date. First, for technical reasons, the antiviral activity of certain
mAbs has only been tested in immunodeficient preclinical animal
models. Second, certain antiviral mAbs originating from one
species have been tested in preclinical models from other species
where constant region-dependent antibody functions are not, or
poorly, preserved. Third, in addition to the paucity of antiviral
mAbs in clinical trials, technical and ethical limitations prevent
certain investigations in human beings. Establishing whether, and
how, mAb-based treatments can orientate antiviral immune
responses towards long-term protective immunity lasting long
after the mAb has disappeared is, however, important as this might
influence the design of mAb immunotherapies of severe chronic
life-threatening viral infections. To address this issue, we have
resorted to the infection of immunocompetent mice by the FrCas
E
retrovirus, as it is one of the rare model systems permitting
extensive analysis of the endogenous immune response after
passive mAb-based immunotherapy under conditions of both
chronic infection and pathological development [15–17].
FrCas
E is an ecotropic retrovirus derived from the Friend
murine leukemia virus (MuLV) [15]. Upon inoculation to
newborn mice under the age of 5 days, it first propagates in
lymphoid organs before penetrating into the central nervous
system (CNS), which leads to a fatal neurodegeneration within 1–2
months [17–19]. In contrast, animals infected at a later stage do
not develop any neurological illness due to the inability of FrCas
E
to penetrate the CNS after day 8 after birth but, instead, may
develop fatal erythroleukemia (see below). We have recently shown
that, when infected newborn mice (day 3 after birth) are briefly
treated by the neutralizing IgG2a/k mAb 667 [17,20,21] shortly
after infection, all animals survive and show no signs of
neurodegeneration or leukemia for more than 1 year [18,22,23].
Survival in good health is not due exclusively to an immediate
effect on the viral load preventing brain infection. It also depends
on the development of an endogenous long-term protective
antiviral immunity that both contains residual viral replication
after clearance of 667 and permits mice to resist to viral challenges.
This immunity is a typical Th1 response comprising a strong
cytotoxic T-cell response against FrCas
E-infected cells [22] and a
potent anti-FrCas
E humoral response principally made up of
IgG2a [18,24]. Moreover, it is rapidly mounted after mAb
treatment and contrasts with the non-protective responses usually
developing in MuLV-infected mice eventually dying from virally-
induced diseases [25,26 and this work]. This observation is
important as it suggests that, in case of suspicion of infection by
life-threatening viruses such as HIV or HCV, rapid administration
of mAb-based immunotherapies before the natural antiviral
response is initiated, may favor the mounting of a potent
protective immunity. This is all the more to be considered that
strong neutralizing antibody responses in the early phase of
infection usually correlate with better long-term control of various
persisting viruses [27–29]. However, only a small fraction of
infected individuals develop such responses as most persistent
viruses induce delayed and weak virus neutralizing antibody
responses that correlate with the establishment of chronic infection
[5,30]. Taking this into account, it is now crucial to understand
how the endogenous protective antiviral response is generated in
mAb-treated animals, why it is so long lasting and whether
administered mAbs actually exert immunomodulatory actions.
Addressing these issues in the FrCas
E system requires detailed
comparison of the antiviral immune responses developing in 667-
treated and -non-treated infected mice, which was not possible in
our original acute neonatal infection model because simply
infected mice cannot mount endogenous immune responses due
to rapid health deterioration (unpublished data). We therefore
developed here a chronic infection setting using older mice, that
leads to death of 100% of the animals by erythroleukemia within
4–5 months, which provides sufficient time for informative
comparison of the two types of immune responses. Our data
clearly point to immunomodulatory effects of the administered
mAb. Moreover, they reveal an important mechanism whereby
antiviral immunity is initiated and maintained in the long-term
via the formation of immune complexes with infected cells. Our
study has consequences for the design of future antiviral
immunotherapies.
Results
Transient 667 mAb treatment efficiently limits viral
propagation and prevents mice from developing FrCas
E-
induced erythroleukemia
First, we created a model of chronic infection by FrCas
E leading
to the death of 100% of mice by erythroleukemia with clear and
synchronous symptomatology. This was achieved by virus
inoculation on day 8 after birth. All mice showed the first
symptoms of erythroleukemia at 2 months post-infection. These
were spleen swelling, due to exacerbated erythroblast proliferation,
and reduction of hematocrits, resulting from combined blockade of
erythropoiesis of infected erythroblasts and exhaustion of non-
infected red blood cells [26]. Mice usually died between day 120–
150 with very low hematocrits (36%61 versus 50%61 in control
animals) and dramatically enlarged spleens (up to 18-fold increase
Author Summary
Monoclonal antibodies (mAbs) constitute the largest class
of bio-therapeutic proteins and are increasingly being
considered as drugs to fight both acute and chronic severe
human viral diseases. Most antiviral mAb-based treatments
conducted so far, whether in humans or in animal models,
have only considered the blunting of viral propagation
through direct virus neutralization. However, mAbs might
also operate via complementary mechanisms owing to
their ability to interact with various components of the
immune system. Using a lethal mouse model of retrovi-
rally-induced leukemia, we report here that a neutralizing
mAb administered to infected mice for a short period of
time can, in addition to its direct effect on viral spread,
induce a strong, long-lasting antiviral immune response
protecting mice from disease development long after the
end of the treatment. Although the initiation and
maintenance of this long-term immunity is multi-factorial,
we demonstrate a crucial role for the immune complexes
formed between antiviral antibodies and infected cells in
this process. Our work reveals a thus far underappreciated
vaccine-like effect of antiviral neutralizing mAbs, which will
have to be considered for future treatment of life-
threatening viral infections.
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prevents infected animals from developing erythroleukemia by
comparing FrCas
E-infected, 667 mAb-treated (infected/treated)
mice to 3 control groups: (i) infected mice not treated with 667
(infected/non-treated), (ii) infected mice treated with an isotype-
matched control mAb (anti-b-2,6-fructosan IgG2a mAb) (infect-
ed/control mAb-treated mice) and (iii) non-infected mice receiving
667 (non-infected/treated). 667 was administered 3 times: 1 hour
after virus inoculation, which is a time sufficient for the
establishment of infection (see ref. [31] and below), and then 2-
and 5 days later (infected/treated mice). Importantly, under these
conditions, 667 became undetectable within less than 20–25 days
post-injection. All non-infected/treated mice and most infected/
treated mice (19 out of 21) survived without pathological
symptoms for the 8 months of the experiments whereas all
infected/non-treated- and all infected/control mAb-treated mice
died of erythroleukemia by 4–5 months post-infection (Figure
S1). Finally, as spleen is a major organ for MuLV replication, we
assessed to which extent 667 could affect viral propagation by
assaying both serum viremia (Figure 1A) and the number of
infected splenocytes (spleen infectious centers or SICs)
(Figure 1B). In infected/non-treated animals, viremia was
transient, peaking (1.7610
6 focus-forming units- or ffu/ml) by
day 8 post-infection with levels that were already high on day 4
post-infection and return to undetectable levels by day 20 (limit of
detection: 10
2 ffu/ml). In infected/treated animals, this peak was
reduced by approximately 4-fold and was narrower (viremia was
undetectable on day 4 post-infection and returned to an
undetectable level earlier than day 20). The effect of 667 was
more marked on SICs than on viremia as infected/non-treated
mice showed a high and constant level of SICs (2–5%) up to death
or experiment termination (day 150) whereas SICs were reduced
by 1000-fold from the earliest time points tested onwards and
became undetectable after day 80 (limit of detection: 1 SIC per
3610
5 splenocytes) in infected/treated animals. Importantly, no
significant rebound of viral propagation, as assayed by SICs, was
observed in infected/treated mice after 20–25 days post-infection.
This suggested the existence of indirect mechanisms induced by
the mAb treatment for reduction/elimination of retrovirus-
producing cells after 667 was cleared off from infected/treated
mice.
Infected/treated mice mount stronger humoral and CTL
anti-FrCas
E immune responses than infected/non-treated
mice
Next, we showed that infected/treated mice developed a
stronger IgG response than infected/non-treated ones
(Figure 1C). In these experiments, infected/non-treated animals
displayed stable, but relatively weak (30–60 mg/ml), anti-FrCas
E
total IgG levels until death or sacrifice of severely leukemic
animals. In contrast, antiviral IgGs accumulated to much higher
levels in infected/treated mice with a peak (400 mg/ml) by day 56
post-infection and a still high level (120 mg/ml) at the end of the
experiment (day 243 post-infection). Although anti-FrCas
E IgG1
and -IgG2a were found in both groups of animals, IgG2a were
always at least 2-fold more abundant and their predominance
increased with time in infected/treated animals (Figure S2A),
suggesting a prominent Th1 T-cell response (also see below).
Finally, we observed that FrCas
E -neutralizing antibody titers were
up to 4 to 8-fold higher in infected/treated mice than in infected/
non-treated ones, indicating that neutralization activity in the two
groups of animals is roughly proportional to the amount of anti-
FrCas
E antibodies (Figure S2B).
We then compared the cellular immune responses against
FrCas
E-infected cells developing in infected/non-treated and
infected/treated animals. To this end, we first assessed the
primary CD8
+ T-cell response against FrCas
E-infected cells during
the first month post-infection by flow cytometry analysis of splenic
CD8
+ T lymphocytes using a MHC class I (MHC I) H2-D
b
tetramer loaded with the GagL peptide (D
b-GagL tetramer) [32].
GagL is an immunodominant H2D
b-restricted epitope conserved
among the different MuLVs strains, which is derived from the
leader region of a glycosylated transmembrane form of the Gag
precursor polyprotein (gPr80
gag). Importantly, gPr80
gag is ex-
pressed by infected cells but not incorporated into virions [33].
Both infected/non-treated and infected/treated mice developed a
transient primary CD8
+ T-cell response already detectable by day
8 post-infection and peaking by day 15 (Figure 2A). However, it
was 2-fold higher in the latter group of mice at the peak of the
response, which was also consistent with the time of SICs
reduction in these mice (Figure 1B). In infected/non-treated
animals, the CD8
+ T-cell response dropped to background levels
by day 22 post-infection (Figure 2A) whereas it was still detectable
in infected/treated mice for at least 56 days, as evidenced by
quantification of D
b-GagL tetramer
+ cells (Figures 2B and 2C).
We also analyzed the phenotype of the GagL peptide-specific
CD8
+ T-cell population remaining after the contraction phase. At
day 56 post-infection, most of the D
b-GagL tetramer
+ CD8
+ T
cells from infected/treated mice were CD44
hi (mean 65%),
whereas only 13% of the CD8
+ T cells in non-infected mice
displayed this phenotype (Figure 2D). Moreover, the majority of
the CD44
hi cells were CD62L
lo (Figure 2D). Interestingly, the
assessment of CD25- and CD127 expression revealed that D
b-
GagL tetramer
+ CD8
+ T cells were CD25
lo and CD127
hi
(Figure 2D and Figure S3). Finally, D
b-GagL tetramer
+ cells
demonstrated effector functions, as revealed by the production of
IFN-c (Figure 2C). Taken together, these results show that
infected/treated mice generated an important CD8
+ T cell
memory pool mainly comprising effector-memory cells.
We then assessed the ability of GagL-specific memory CD8
+
T cells from infected/treated mice to trigger efficient secondary
responses. In these experiments, animals were challenged with
FrCas
E-infected splenocytes on days 56 and 116 post-infection
(infected/non-treated and infected/treated mice) and analyzed
9 days later for both the expansion and the killing activity of this
cell pool. No significant memory response was found in
infected/non-treated animals (Figure 3A), although the pres-
ence of a weak antiviral CD8
+ T-cell response below the
sensitivity of the assay could not formally be excluded (see
below). In contrast, robust responses were detected in infected/
treated mice at both time points tested (Figure 3A)( c o m p a r et o
the response observed before challenge with FrCas
E-infected
cells in Figures 2B and 2C). Moreover, a strong in vivo
cytolytic activity (50-80%) directed to splenocytes loaded with
the GagL peptide was observed in all infected/treated mice.
Importantly, 3 out of the 5 infected/non-treated mice showed a
weak but detectable cytolytic activity (9-20%) while the other 2
showed a basal cytolytic activity similar to that found in control
non-infected/non-treated animals (,2.76%) (Figure 3B).
Thus, CD8
+ memory T cells from infected/treated mice can
develop functional secondary responses.
Lastly, we found that infected/treated mice maintained a
functional anti-FrCas
E cellular response in the long-term in a
challenge experiment conducted 8 months post-infection in 10
infected/treated mice. Nine of the 10 mice had normal
hematocrits and no sign of splenomegaly for the duration of the
experiment, whereas one of them (mouse 172) showed clinical
Vaccinal Effect of Passive Antiviral Immunotherapy
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E IgG responses between infected/treated and infected/non-
treated mice. Serum viremia, presented as focus-forming units (ffu)/ml (A) and spleen infectious centers (B) were assayed as described in the Methods
Vaccinal Effect of Passive Antiviral Immunotherapy
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partial protection by 667. Notably, (i) all mice except mouse 172
revealed a memory cellular CD8
+ T-cell response in both flow
cytometry- and in vivo CTL assays (Figure 3C and 3D) and (ii) no
(7/9 mice) or very few (2/9 with 0.006 and 0.16%) SICs were
found in the 9 non-leukemic mice. Thus, a transient 667 treatment
shortly after infection led to a functional long-lasting memory CTL
response whereas infected/non treated mice only developed a
weak primary CTL response. This is consistent with the fact that
most individuals of the former group did not develop leukemia
while all of the latter group did.
The 667 mAb enhances the virus-specific CD8
+ T-cell
response
To understand the enhanced cellular immunity mounted by
infected/treated mice, we tested whether ICs formed by 667 and
viral antigens during passive immunotherapy could prime the
antiviral CTL response more efficiently than FrCas
E alone. To
this aim, bone marrow-derived dendritic cells (BMDCs) were
pulsed with (i) ICs made up of FrCas
E +667 (Fr-IC) or FrCas
E-
infected splenocytes +667 (SpFr-IC) or (ii) non-complexed FrCas
E
or splenocytes simply infected with FrCas
E (SpFr). Their ability to
stimulate the proliferation of CFSE-labeled CD8
+ naive T cells
from transgenic mice (GagL-TCR-TG) expressing a TCR
specific for H2D
b-restricted GagL [34] was then assessed in vitro.
Unloaded- and GagL-loaded BMDCs were used as negative and
positive controls, respectively. No GagL-TCR-TG CD8
+ T-cell
proliferation was observed in the presence of either FrCas
E alone
or FrCas
E complexed with 667 (Fr-IC) (Figure 4A). This was not
surprising as GagL is derived from gPr80
Gag, which is not
incorporated into virions [33]. In contrast, both infected
splenocytes (SpFr) and infected splenocytes complexed with the
667 mAb (SpFr-IC) stimulated proliferation (Figure 4B)w i t ha
stronger effect for SpFr-IC. This showed that cellular ICs were
more efficient than simply infected cells at stimulating the
proliferation of FrCas
E-infected cell-specific CTLs by BMDCs
(Figure 4B and Figure S4). We next addressed whether this
increased T cells proliferation was dependent on FccRs expressed
by DCs. This turned out to be the case as proliferation of GagL-
specific CD8
+ T cells was decreased (i) when the experiment was
conducted in the presence of a FccR-blocking mAb (2.4G2 mAb;
[35]) or when (ii) cellular ICs were made with a F(ab)’2 fragment
of 667 (SpFr-F(ab)’2) instead of the whole 667 mAb (Figure 4C).
Importantly, we extended these observations to the in vivo
situation. Two different amounts of FrCas
E-infected splenocytes,
either complexed with 667 (SpFr-IC and SpFr/1:10-IC, respec-
tively) or non-complexed (SpFr and SpFr/1:10, respectively),
were administered i.v. to mice and CTL responses were analyzed
9 days later. ICs were more efficient at both stimulating
proliferation of GagL-specific CD8
+ T cells (Figure 5A and
Figure S5) and enhancing CTL responses against infected cells
(Figure 5B and Figure S5) than non antibody-complexed
infected splenocytes regardless of the amount of cells used. These
results indicated that 667-involving cellular ICs enhance CD8
+
T-cell responses in vivo.
667 enhances uptake of infected cells and induces more
efficient activation of DCs
Antigens in the form of ICs have already been reported to be,
not only more efficiently taken up by DCs, but also better
activators of these cells than free antigens [13,36]. As a first step
to explain the stronger anti-FrCas
E CTL responses presented in
Figures 4 and 5, we therefore reasoned that DCs could take up
SpFr-IC more efficiently than SpFr, which would lead to their
stronger activation. Uptake by DCs was investigated as follows.
First, SpFr were stained with the membrane-labelling dye
PKH26 and complexed, or not, with 667. Then, they were
given to DCs in the presence or in the absence of the FccR-
blocking 2.4G2 mAb for various periods of time before flow
cytometry quantification of the PKH26 fluorescence present in
DCs. The data of Figure 6A show that SpFr-IC were taken up
faster and more efficiently than SpFr and that differential uptake
efficiency was dependent on FccRs. These data were consistent
with those of Figure 4C showing that the FccR-blocking mAb
inhibits GagL-TCR-TG CD8
+ T-cell proliferation by SpFr-IC-
activated BMDCs. We then quantified the abundances of the
CD40 and CD86 co-stimulatory molecules at the surface of
BMDCs cultured in the presence of SpFr or SpFr-IC, as these
markers are classically used to monitor DC activation. Both of
them were slightly but reproducibly more expressed in the latter
case (Figure 6B), indicating better activation of BMDCs by
SpFr-IC.
As a significant fraction of DCs can express retroviral proteins
in mice infected with MuLVs [37], we also considered that
cellular ICs may have favored DC-, or DC precursor, infection
by FrCas
E and, hence, led to the generation of DCs with altered
properties possibly influencing CTL responses in infected/
treated mice. In a first step, we asked whether uptake of SpFr,
complexed or not with 667, could be followed by productive
infection of DCs. This was achieved by assaying Env expression
48 hours after giving SpFr or SpFr-IC to BMDCs. As positive
controls, SpFr or SpFr-IC were given to infection-sensitive Mus
dunni fibroblasts in parallel experiments. Thirty and 6% of Mus
dunni cells turned out to be positive for Env after infection in the
presence of SpFr or SpFr-IC, respectively, lower infection in the
latter case being consistent with a neutralization action of 667
(Figure 6C). In contrast, BMDCs were negative whatever the
condition tested (Figure 6C). This was not surprising as
BMDCs are essentially post-mitotic cells under the experimental
conditions used and MuLVs require mitosis for proviral
integration and subsequent viral function expression. As
proliferating FccR-expressing precursors of DCs might possibly
be infected in vivo and lead to the generation of DCs with altered
properties due to the expression of retroviral proteins, we also
monitored Env positivity of splenic DCs in both infected/non-
treated and infected/treated mice in the post-infection period
(Figure 6D). 20% of splenic DCs were Env-positive in
infected/non-treated mice on both days 8 and 15 post-infection.
In contrast, only 1% and 3% of their counterparts were positive
in infected/treated mice at the same time points and no Env-
positive cell was detected at a later time (day 35). Thus, rather
section. Two groupsof 8 day-old micewere infectedwith FrCas
E. Onegroup was treated with 667(infected/treated) 1 hour post-infectionandon days 2
and 5 post-infection and the other was not treated (infected/non-treated). A group of mice that was not infected but that was treated with 667 (non-
infected/treated), was taken as a negative control (not shown). The data presented are representative of 2 independent experiments. Each time point is
the average of values obtained from 2 animals per time point except in the case of day 8 (5 animals). Non-infected/treated mice were negative for both
serum viremia and SICs and are not presented. Error bars indicate SEM. Total anti-FrCas
E IgGs (C) were assayed by ELISA. Mice were infected and treated
as in A and B. One of 2 independent experiments with similar outcomes is presented. The data are the average of values obtained from at least 10
animals per time point. Non-infected/treated mice were negative for anti-FrCas
E IgGs and are therefore not presented. Error bars indicate SEM.
doi:10.1371/journal.ppat.1000948.g001
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+ T-cell responses against FrCas
E-infected cells. Mice were infected and treated, or not, as in Figure 1. (A) Kinetics of
the primary anti-FrCas
E CTL response. Spleen cells from 2 mice of each group per time point (days 8, 22 and 28 post-infection) and from 5 mice per
Vaccinal Effect of Passive Antiviral Immunotherapy
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the treatment by 667 diminishes it, presumably because reduced
viral spread in infected/treated mice limits infection of DC
precursors. In conclusion, stronger stimulation of anti-FrCas
E
CTL responses by cellular ICs correlates with more efficient
uptake by DCs followed by more efficient activation but is
unlikely to involve infection of DCs or DC precursors.
Enhancement of CD8
+ T-cell response against infected
cells by endogenous anti-FrCas
E antibodies generated in
infected/treated mice
As infected/treated mice developed a long-lasting CD8
+ T-cell
response correlating with high titers of anti-FrCas
E antibodies, we
next studied whether the humoral response in infected/treated
mice could contribute to the long-lasting maintenance of the CTL
group at day 15 post-infection were stained with an anti-CD8 mAb and the D
b-GagL tetramer and analyzed by flow cytometry. (B–D) Phenotypic
characterization of primary CD8
+ T-cell responses in infected/treated animals. Mice were infected and treated as in Figure 1. CD3
+ cells were isolated
by negative selection from the spleens of 4 infected/treated- and 2 infected/non-treated mice on day 56 post-infection. Half of the CD3
+ cells were
then stained with the D
b-GagL tetramer and anti-CD8, anti-CD44, anti-CD62L and anti-CD25 mAb and analyzed by flow cytometry. In parallel, the
other half of the CD3
+ cells were incubated with PMA-ionomycin plus brefeldin A and IFN-c production by tetramer
+CD8
+ T cells was assessed by
intracellular staining. The statistical significance of data between infected/treated- and infected/non-treated mice was established using the Student’s
t test (*P=0,045). (B) Assay of GagL-specific CD8
+ T cells in infected/treated and infected/non-treated mice on day 56 post-infection. (C–D) Phenotypic
characterization of GagL-specific CD8
+ T cells on day 56 post-infection. Data from 1 age-matched non-infected/non-treated (naive) mouse and 4
infected/treated mice are presented.
doi:10.1371/journal.ppat.1000948.g002
Figure 3. Long-term CTL memory responses in infected/treated animals versus control mice. Mice were challenged with FrCas
E-infected
splenocytes on days 56 or 116 post-infection and 9 days later CD8
+ T-cell responses were assessed by measuring both the percentage of GagL-specific
CD8
+ T cells and specific in vivo CTL activity as described in the Methods section. (A–B) Assay of GagL-specific memory CTL responses in infected/treated
and infected/non-treated mice challenged on days 56 or 116 post-infection. Infected/treated and infected/non-treated mice were challenged on day 56 (3
mice per group) or on day 116 (2 mice per group). Non-challenged age-matched non-infected/non-treated mice (3 on day 56 and 2 on day 116) were
used as controls. The statistical significance of data between the infected/treated group and the other two groups was established using a non-
parametric one-way ANOVA test with Dunn’s multiple comparison post-test (*P,0,05). (C–D) Assay of GagL-specific memory CTL responses in infected/
treated mice challenged at month 8 post-infection. Eight month-old infected/treated mice were challenged with FrCas
E-infected splenocytes. Non-
challenged aged-matched non-infected/non-treated mice were used as controls. Statistical significance of data between infected/treated- and non-
infected/non-treated mice was established using the Student’s t test (**P=0,0034; *** P=0,0015). Bars indicate mean values.
doi:10.1371/journal.ppat.1000948.g003
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PLoS Pathogens | www.plospathogens.org 7 June 2010 | Volume 6 | Issue 6 | e1000948Figure 4. Stimulation of proliferation of GagL-TCR-TG CD8
+ T cells by 667 and sera from infected/treated mice. BMDCs were prepared
and exposed to various sources of antigen. The day after, they were co-cultured with CSFE-labeled CD8
+ T cells prepared from lymph nodes from
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pooled sera from either 4 infected/non-treated mice (pool 1)
sacrificed on day 115 post-infection or 4 infected/treated mice
(pool 2) sacrificed on day 243 were used to form ICs with infected
splenocytes in the T-cell proliferation assay described above.
Because anti-FrCas
E antibody titers were higher in infected/
treated mice (120 vs. 70 mg/ml), we compared the CD8
+ T-cell
priming efficiencies of the 2 serum pools at both identical dilutions
and at identical anti-FrCas
E antibody concentrations. A GagL-
TCR-TG CD8
+ T cell proliferation was detected in the presence
of sera from infected/treated mice (pool 2) but not in the presence
of sera from infected/non-treated mice (pool 1) when used at
identical dilutions (Figure 4D). In contrast, no proliferation was
seen with either pool of sera when used at identical anti-FrCas
E
concentrations (pool 1 versus pool 2-diluted) (Figure 4D). This
indicated that endogenous antibodies from infected/treated mice
promoted CD8
+ T cell proliferation through the formation of ICs
with FrCas
E-infected cells. However, this effect was dose-
dependent, which may explain why the CD8
+ T-cell response
was weaker in infected/non-treated mice than in infected/treated
ones as the former displayed lower titers of anti-FrCas
E antibodies.
These results suggest that the enhanced endogenous humoral
response induced in infected/treated mice plays an important role
in the maintenance of the cellular response after the administered
667 mAb has disappeared.
667 and anti-FrCas
E antibodies endogenously generated
in infected/treated mice show cytolytic activity in vivo
Finally, it was important to assess whether 667 and anti-FrCas
E
antibodies generated endogenously in infected/treated mice could
lyse infected cells in vivo. To this end, we injected i.v. a mixture of
non-infected- and FrCas
E-infected splenocytes in 2 month-old
naive mice. This was followed by i.p. administration of either (i)
667 or control PBS or (ii) pools of 2 sera from 3 month-old non-
infected/non-treated, infected/non-treated or infected/treated
mice. In the case of 667, the ratio of the two cell types was
assayed by flow cytometry of circulating blood cells 5 hours later.
In addition to a spontaneous basal cell lysis activity, we observed a
rapid cytolytic activity against FrCas
E-infected cells due to 667
(Figure 7A). For the experiments with the pools of sera,
comparable volumes of sera were injected to the mice and
cytolysis was assayed 24 hours later (Figure 7B). Cytolysis activity
of sera from infected/non-treated mice was comparable to
spontaneous cytolysis in control naive mice whereas that of sera
from infected/treated animals was much stronger. Thus, both 667
and anti-FrCas
E antibodies contained in sera from infected/
treated mice can lyse FrCas
E-infected cells in vivo. However, the in
vivo cytolysis of infected cells observed by 667 administration was
higher than the one observed by sera from infected/treated mice.
This was most probably due to the fact that volume of pooled sera
used contained about 100 mg of anti-FrCas
E antibodies while
200 mg of 667 mAb were administrated, suggesting that anti-viral
antibody concentration might be a critical factor to induce efficient
cell lyses of infected cells.
As a last step, we addressed whether antibody-mediated lysis of
infected cells was dependent on NK cells and/or complement. To
this aim, new in vivo cytolysis experiments were conducted after
either having depleted NK cells by administration of an anti-asialo
GM1 antibody or inactivated complement activity through
injection of the cobra venom factor. To increase the efficiency of
our assay, the mixture of non-infected- and FrCas
E-infected
splenocytes was, this time, pre-incubated with either the 667 mAb
or anti-FrCas
E antibodies from infected/treated mice serum prior
to administration. In the latter case, we also increased the quantity
of anti-FrCas
E antibodies administrated to mice by pooling sera
from mice with high serum anti-viral antibody concentrations. NK
cell depletion resulted in a dramatic decrease of infected-cell lysis
by both the 667 antibody (Figure 7C) and the sera from infected/
treated mice (Figure 7D) whereas inactivation of the complement
system had no detectable effect (Figure 7C and 7D). This
pointed to a role for ADCC in infected lysis by both 667 and the
endogenous antiviral humoral response of infected/treated mice.
Discussion
Our data point to an immunomodulatory effect of the 667 mAb,
which permits FrCas
E-infected mice to mount a long-lasting
protective immunity comprised of both a strong neutralizing
humoral response and a robust CTL contribution that subtly
interact to protect individuals from virally-induced diseases in the
long-term. This ‘‘vaccine-like’’ effect, which lasts long after the
termination of the treatment, contrasts with the non-protective
immune response in infected/non-treated controls. If applicable to
other persistent viral infections, our observation will have
important therapeutical consequences for mAb-based immuno-
therapies. One of our most notable findings is that, not only the
generation of an efficient primary CTL response, but also the
activation of the long-lasting antiviral memory CD8
+ T cells
involves the formation of ICs between antibodies and infected
cells. Therefore, our data strongly suggest that, antibodies
targeting proteins present, not just on virions, but also on the
surface of infected cells should have a crucial advantage for
efficient treatment of virally-induced diseases in the context of
passive immunotherapies.
How might protective antiviral immunity be initiated in
667-treated, FrCas
E-infected mice?
Several non-exclusive mechanisms may explain the long-term
consequences of the 667 treatment on endogenous antiviral
GagL-TCR-TG mice transgenic for a TCR recognizing the H2D
b-restricted GagL peptide. Proliferation was assessed 5 days later by flow cytometry. (A)
Control experiments. BMDCs were cultivated with the GagL peptide (used as positive control), FrCas
E and FrCas
E ICs made with 667 (Fr-IC). Culture
medium (RPMI) served as a negative control. (B) Stimulation of CD8
+ T cells priming by FrCas
E-infected splenocytes in the presence and in the absence of
667. Non-infected (Sp) or infected splenocytes (SpFr) were incubated in the presence of 2 concentrations of 667 (Sp-IC and SpFr-IC, respectively). A
typical experiment out of 3 independent ones with similar outcomes is presented. The statistical significance between the SpFr and SpFr-IC groups in
these 3 experiments was established using the Student’s t test (*P=0,0003) (see Figure S4). (C) Stimulation of CD8
+ T cells priming by FrCas
E-infected
splenocytes complexed with either the 667 F(ab’)2 fragment or the whole 667 mAb in the presence and in the absence of the FccR-blocking antibody.
FrCas
E-infected splenocytes (SpFr) were complexed with either 15 mg of the 667 F(ab’)2 (SpFr- F(ab’)2) or with 10 mg of the 667 mAb (SpFr-IC). SpFr-IC
were co-cultured with BMDCs previously incubated (SpFr-IC + anti-FccR), or not, with the FccR-blocking antibody. Non-infected splenocytes
incubated in the absence (Sp) or in the presence of 10 mg of 667 (Sp-IC) were used as control. (D) Stimulation of CD8
+ T cells priming by FrCas
E-infected
splenocytes in the presence of sera from infected/treated mice or infected/non-treated mice. Pool 1 corresponds to sera from 4 infected/non-treated
animals sacrificed on day 115 post-infection whereas Pool 2 corresponds to the sera of 4 infected/treated mice sacrificed on day 243. ‘‘Pool 2-diluted’’
corresponds to Pool 2 with anti-FrCas
E antibody concentration adjusted to that of Pool 1. Similar results were obtained in 2 independent experiments
with individual serum samples from mice of each group.
doi:10.1371/journal.ppat.1000948.g004
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+ T-cell responses against FrCas
E by ICs. SpFr or SpFr-IC were administered i.v. to non-infected/non-
treated mice. Four groups of mice (n=3) where used: two of them were injected with either 2610
6 or 2610
5 FrCas
E-infected splenocytes (SpFr and
SpFr 1:10, respectively) in the absence of 667, and the other two were injected with the same amount of FrCas
E-infected splenocytes complexed to
150 mg of 667 (SpFr-IC and SpFr 1:10-IC respectively). Nine days later, they were tested for the expansion of GagL-specific CD8
+ T cells and for CTL
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mAb on both plasma viremia and SICs before an adaptive
immune response could emerge. This suggests that an immediate
effect of 667 might be the blunting of viral propagation that would
indirectly provide time for the immune system to mount a
protective antiviral immunity before being overwhelmed. Our
data also strongly suggest that the potent effect of 667 on the viral
load is due to, not only its neutralizing activity, but also to its in vivo
cytolytic activity against FrCas
E-infected cells mainly through
ADCC-mediated mechanisms. Secondly, due to 667 ability to
enhance the priming of CD8
+ T cells directed to FrCas
E-infected
cells, it is unlikely that limiting viral propagation is the sole
mechanism whereby this mAb impacts on endogenous humoral
and cellular anti-FrCas
E responses. Rather, direct immunomod-
ulatory mechanisms involving the formation of ICs, not only with
viral particles but also with infected cells exposing Env at their
surface, seem essential. Indeed, IgGs have already been shown to
act as natural adjuvants in a process called antibody feedback
regulation to enhance immune responses against antigens they are
specific for in various settings, including infection by pathogens
[38]. One major mechanism whereby administered antibodies
operate is interactions of ICs with the FccRs expressed by various
immune cell types, including DCs. Such interactions lead to both
enhanced humoral- [39–42] and stronger CD4
+ and CD8
+ T-cell
responses due to more efficient DC activation/maturation
characterized by better generation and presentation of antigenic
peptides [14,36,43]. It is however important to stress that the
potential therapeutic effect of IC-DC interactions has, thus far,
principally been studied in the context of antitumoral immuno-
therapies using in vitro techniques [24,44] or in vivo approaches that
mainly rely on the simplified OVA model system and/or the
grafting of in vitro IC-loaded DCs [14,36,45], but it has never been
addressed in the context of real persistent/lethal viral infections.
Therefore, our work demonstrates for the first time that cellular
ICs formed during a mAb-based passive immunotherapy can be
crucial for inducing a long lasting protective antiviral immunity. It
also shows that interactions of such IC with FccRs expressed on
DCs are important in the induction of enhanced CD8
+ T-cell
responses. Supporting the idea that our findings may also apply to
infections by persistent viruses other than FrCas
E, (i) enhanced
humoral responses have been described upon use of ICs in
therapeutical vaccination-based treatments of HBV infection [46]
and (ii) in vitro stimulation of peripheral blood mononuclear cells
from SIV-infected macaques with ICs made up of p55
gag + anti-
p55
gag IgGs led to more efficient stimulation of precursor CTLs
against SIV-infected cells than stimulation by p55
gag alone [47].
However, no data concerning protection from disease was
reported in the latter study.
How does 667 induce long-lasting protective humoral- and
cellular anti-FrCas
E immunities? IgG responses were significantly
different in intensity and antiviral activity between infected/
treated and infected/non-treated mice (Figure 1C), suggesting an
immunomodulatory effect of 667 affecting both the magnitude
and the quality of the anti-FrCas
E humoral response. Importantly,
an enhanced antibody response following short passive immuno-
therapy is unlikely to be exclusive to our model as intensive
treatment of juvenile SIV-infected macaques with anti-SIV
hyperimmune serum Igs accelerated the appearance of neutraliz-
ing antibodies, which correlated with delayed onset of the disease
in some animals [48]. As ICs play an important role in the
development of antibody responses via different modes of action
[13,40–42], further work will be needed to address how 667-
containing ICs can induce enhanced humoral immunity. As for
the cellular response, the most likely scenario for enhanced CTL
response in infected/treated mice is that 667 would initially target
FrCas
E-infected cells and lyse them by ADCC. The resulting
cellular immune complexes would then be efficiently taken up by
DCs, owing to interactions with FccRs, for more efficient
stimulation of effector cells of the immune system. Several of our
observations support this scenario: (i) uptake of FrCas
E-infected
cells by DCs is increased by 667 and this increase is inhibitable by
aF c cR-specific antibody (Figure 6A), (ii) DCs are more efficiently
activated by SpFr-IC than by SpFr, at least as assayed by CD40,
and CD86 expression (Figure 6B), (iii) 667-complexed FrCas
E-
infected splenocytes are more efficient at inducing anti-FrCas
E
CD8
+ T-cell responses than non-mAb-complexed cells both in vitro
(Figure 4B) and in vivo (Figure 5) and (iv) such enhanced CD8
+
T-cell responses are dependent on IC interactions with FccRs
expressed on DCs (Figure 4C). One challenge is now to elucidate
the intimate cellular and molecular mechanisms whereby cellular
IC-activated DCs can induce stronger immune responses than
simply infected cells. Obvious non exclusive processes that need to
be assessed include (i) the facilitation of DC migration to lymphoid
organs, (ii) the increased production of proinflammatory cytokines
production and/or decreased production of immunosuppressive
ones or (iii) the better processing of cellular antigens and/or
presentation to effector cells as reported in other systems
[13,36,43,45,49]. Moreover, one will have to take into consider-
ation that, in vivo, cellular IC-activated DCs may interact with, not
only CTLs, but also other effector cells such as CD4
+ lymphocytes.
Whatever the mechanisms involved, our work importantly shows
that uptake of cellular ICs allows the presentation of the full viral
antigenic repertoire, including determinants not incorporated into
virions but expressed only in infected cells (as shown here by the
presence of CD8
+ T cells specific for GagL epitope from gPr80
gag).
This is probably crucial for rejection of infected/leukemogenic
cells by CTLs, as suggested by efficient lysis of GagL-loaded
splenocytes administered to infected/treated mice (Figures 3B,
3D and 5B). Supporting this idea, the coating of apoptotic tumor
cells with antibodies enhances antitumoral immune responses in
various settings [13,24,44,50]. Finally, as 667 is able to target
infected cells in vivo, it is plausible that 667-induced cell lysis
through ADCC-mediated mechanisms may create an inflamma-
tory environment favoring uptake, processing and presentation of
viral antigenic determinants by DCs to T cells as reported in the
case of lytic anti-tumor mAb [51,52]. In conclusion, 667/infected
cells ICs appear to have a two-fold effect: they enhance
quantitatively and qualitatively viral antigen presentation, which
induces potent CTL responses directed to infected cells.
How might protective antiviral immunity be maintained
in infected/treated mice after the disappearance of 667?
Our data strongly suggest that long-term protective antiviral
immunity in infected/treated mice relies on a complex relationship
between humoral and cellular anti-FrCas
E immunities following
the primary response. In this respect, a first question is why the
humoral anti-FrCas
E response lasts so long and is so high in
infected/treated mice as compared to infected/non-treated ones?
activity in vivo as described in Figure 3. Non-infected/non-treated mice with no further treatment were used as controls (A). Proliferation of GagL-
specific CD8
+ cells. The statistical significance between groups was established using the Student’s t test (*P=0,0106; **P=0,0049; ***P=0,0071:
****P=0,0352). (B) CTL activity against GagL-loaded splenocytes. A representative mouse of each group is presented.
doi:10.1371/journal.ppat.1000948.g005
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stimulation by residual infected cells with an intensity positively
correlated to the number of these cells as (i) the humoral response
begins to decrease by the moment SICs become undetectable
(Figure 1B–C) and (ii) individual animal analysis at month 8 post-
infection/treatment (unpublished data) shows that anti-FrCas
E
antibody titers are higher in mice with residual SICs compared to
those with undetectable SICs (the virus probably not being
eradicated in the latter mice). A second important issue is why the
CTL response is maintained at a low level in infected/treated
animals except under conditions of challenge? As endogenous anti-
FrCas
E antibodies can lyse FrCas
E-infected cells, we hypothesize
that, after establishment of persistent infection, the CTL pool is
weakly or no longer solicited, as suggested by the low levels of
effector-like memory-Tcells detected in unchallenged infected/
treated mice (Figure 2). This would avoid exhaustion by
overstimulation and, consequently, preserve the possibility of
strong anamnestic responses in case of virus reactivation as
described in various infection systems [53,54]. Supporting this
idea, virus-specific antibodies have already been shown essential
for long-term maintenance of the memory CTL response upon
infection of mice by the lymphocytic choriomeningitis virus
(LCMV) [27,53]. Finally, it is also important to consider that the
humoral response might facilitate the activation of memory CTLs
in case of viral reactivation/reinfection (mimicked here by a
challenge with infected cells), as we show that anti-FrCas
E
antibodies, through the formation of ICs, can enhance the
proliferation of CTLs specific for infected cells (Figure 4D).
Strengthening this idea, elicitation of such specific CTL responses
by adequate levels of antibodies directed against tumor antigens
has recently been reported in therapeutical vaccination experi-
ments against cancer cells [55]. Thus, our work shows that the
endogenous immune response induced by the immunotherapy can
take over the administered mAb to contain viral propagation long
after the end of the treatment. It also suggests that this antiviral
immunity is capable of self-maintenance through a complex
balance between the humoral and cellular arms of the immune
response with a critical role for ICs.
MAb-based immunotherapies and treatment of human
chronic infections
Most available therapies against severe chronic viral infections
are based on the use of pharmacological drugs and/or interferon
[56,57]. Their aim is to inhibit viral spread/replication via various
mechanisms but not to enhance the antiviral immune response of
treated patients. In certain cases, they can even lead to ‘‘immune
amnesia’’ due to the dramatic decrease of viral antigens, as it has
been reported in the case of HIV [58–60]. Therefore, these
therapeutical approaches clearly depart from ours, which shows
that, in addition to its direct antiviral effect, a passive
immunotherapy can also favor the mounting of a protective
antiviral immunity. One important mechanistic explanation for
the different immune outcomes between the two types of
treatments is that antiviral drugs do not enhance viral antigen
presentation by APCs whereas antiviral mAbs can through an
opsonized antigen-based process, as shown here. Consequently,
our work identifies a thus far underappreciated immunomodula-
tory property of antiviral mAbs and underlines a possibly major
difference with other antiviral drugs.
Our experiments were conducted in the context of early post-
exposure therapy of young animals with still-developing immune
systems. Moreover, the neutralizing mAb was administered rapidly
after infection. It is therefore possible that the application of such
passive immunotherapy-stimulated antiviral immunity approaches
may be limited to cases of suspicion of infection in young
individuals by life-threatening viruses such as HCV or HIV. An
important challenge will now be to determine whether passive
mAb-based immunotherapies can also influence the immune
response of chronically infected adult mice. Whatever the answer
to this question, the fact that our experiments were conducted with
young animals still in the period of immune system maturation
raises the possibility that a possible first application of this effect
might be the treatment of mother-to-child transmission of HIV for
two reasons: the need of novel therapies because of spontaneous
resistances of certain patients to current chemotherapies and the
availability of neutralizing mAbs against this virus (see introduc-
tion). During the first 12–48 months, maternally-transmitted
neutralizing antibodies from immunized/vaccinated mothers
protect babies and infants from various acute infections and may
turn incoming viruses into effective vaccines in a process called
‘‘natural vaccination’’ [61]. However, mothers who are HIV
carriers usually do not produce neutralizing antibodies and can
transmit the virus to babies at birth and natural vaccination cannot
take place. An important question would therefore be whether the
administration of exogenous anti-HIV mAbs to perinatally
infected babies could reproduce the ‘‘natural vaccination’’
observed in the case of other viral infections. The fact that, as
already cited, the treatment of juvenile SIV-infected macaques
with anti-SIV hyperimmune serum Igs accelerated the appearance
of neutralizing antibodies and was followed by delayed onset of the
disease in certain monkeys [48] provides a support to this idea.
Methods
Ethics statement
All experimental procedures performed in this study are in
accordance with the local animal facility ‘‘ComEth’’ Institutional
Review Board guidelines, and have been approved by the local
animal facility ‘‘ComEth’’ Institutional Review Board under the
supervision of the French LR Regional CEEA ethic committee on
animal experimentation (Chairman: Pr M Michel, Montpellier).
Viral stocks
FrCas
E viral stocks were produced as described in [17].
Monoclonal antibody and F(ab’)2 fragments production
The anti-MuLV Env mouse 667 (IgG2a) and 678 (IgG1) mAbs
[21] were purified as previously described [20]. The 667 F(ab’)2
was prepared as follows: 667, at concentration of 3 mg/ml in
20 mM sodium acetate (pH 4.0) was mixed with pepsin at
Figure 6. Influence of FrCas
E-infected cell ICs on BMDCs. (A) Uptake of SpFr and SpFr-IC by DCs. PKH26-labelled SpFr or -SpFr-IC were given to
BMDCs and uptake was quantified by flow cytometry in the presence, or in the absence, of the 2.4G2 FccR-blocking mAb. One experiment out of 3
with similar outcomes is presented. (B) BMDCs activation. BMDCs were incubated for 24 hours in the presence of SpFr, SpFr-IC or LPS before flow
cytometry assay of CD40 and CD86. One representative experiment out of 3 independent with similar outcomes is presented. (C) Assessment of
productive in vitro BMDC infection. BMDC were co-cultured with SpFr or SpFr-IC for 48 hours before flow cytometry assay of MHC-II
+Env
+ cells.
Infection-sensitive Mus dunni fibroblasts were used as positive controls in parallel experiments. (D). Assay of Env-expressing DCs in vivo. MHC-II
+Env
+
splenocytes from infected/treated- and infected/non-treated mice were assayed by flow cytometry at days 8, 15 and 35 post-infection.
doi:10.1371/journal.ppat.1000948.g006
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The mixture was incubated for 7 hours at 37uC. The undigested
mAb was removed by protein A column chromatography. The
unbound fraction was collected as the F(ab9)2 and purity was
checked by sodium dodecyl sulfate-polyacrylamide gel electropho-
resis analysis. The activity of the F(ab9)2 was shown identical to
that of intact 667 by an in vitro plaque reduction neutralization
assay. The control anti-b-2,6-fructosan IgG2a mAb is from Sigma.
The FccR-blocking 2.4G2 mAb [35], which recognizes both
CD16 and CD32, was purchased from BioXcell and the anti-
asialo GM1 mAb used for NK cells depletion was from Wako.
Virus titers and in vitro neutralization activity assays
Viral titers were determined using a focal immunofluorescence
assay (FIA) [62] as previously described [18,20,22]. Virus neutrali-
zation activity of mouse sera, was assayed as previously described
Figure 7. Cytolytic activity against FrCas
E-infected cells of 667 and of anti-FrCas
E antibodies endogenously produced in infected/
treated mice. In vivo cytolysis activities were assayed after administration of CFSE-labeled FrCas
E-infected splenocytes (SpFr) followed by
administration of antibodies from various sources and cytometry analysis after 5 or 24 hours. (A) Cytolytic activity of 667. SpFr were administered i.v.
and, then, 667 or PBS i.p. Values are the average 6 SEM of experiments conducted with 4 mice per condition. The statistical significance was
established using the Student’s t test (*P=0,0007). (B) Cytolytic activity of sera from infected/treated- and infected/non-treated mice. After
administration of SpFr, three groups of 4 mice each were treated with equivalent volumes (175 ml) of pools of sera from 2 non-infected/non-treated-,
2 infected/non-treated- and 2 infected/treated mice. Values are the average 6 SEM of experiments conducted with 4 mice per condition. Statistical
significance of sera from infected/treated group versus the other two groups was determined by a non-parametric one-way ANOVA test with Dunn’s
multiple comparison post-test. *P,0,05. (C) Cytolytic activity of 667 in mice treated with either anti-NK antibodies or cobra venom factor. SpFr mixed
with 667, or PBS for control, were administered i.v. to mice treated or not with either anti-NK antibodies or the cobra venom factor as described in the
Methods section. The values are the average 6 SEM of experiments conducted with 7 mice per condition. The statistical significance of the data
obtained with sera from the infected/treated group versus those obtained in the other two groups was established using a non-parametric one-way
ANOVA test with Dunn’s multiple comparison post-test. (*P,0,05). (D) Cytolytic activity of sera from infected/treated in mice treated with anti-NK
antibodies or cobra venom factor. SpFr mixed to 175 ml of pools of sera from 4 infected/treated were administered i.v. to mice treated or not with
either anti-NK antibodies or the cobra venom factor, as described in the Methods section. The values are the average 6 SEM of experiments
conducted with 2 mice per condition. Statistical significance of sera from infected/treated group versus the other two groups was not assessed due
to the reduced number of mice per condition.
doi:10.1371/journal.ppat.1000948.g007
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2 FrCas
E ffu (focus-forming units)were diluted ina
1:1 ratio with serum samples and incubated at 37uCf o r1h o u r .
Mixes were used to infect target cells overnight. Cells were allowed to
reach confluence, at which time ffu were scored by FIA.
Viral infection and follow-up of mice
Inbred 129/Sv/Ev mice (H-2D
b haplotype) were used in this
study. Eight day-old mice were infected i.p. with 100 ml of a virus
suspension containing 5610
5 ffu/ml and treated or not with 30 mg
of 667 or the control anti-b-2,6-fructosan mAb one hour post-
infection and on days 2 and 5 post-infection by i.p. administration.
Mice were examined at regular intervals for clinical signs of
erythroleukemia (spleen swelling and reduction in hematocrits).
Mice were sacrificed when their hematocrits reached 35% to avoid
unnecessary pain, as they would die within the next days. Spleens
were weighted either after death or on the day of sacrifice. Viremia
was assayed from sera as previously described [17,18].
ELISA of anti-FrCas
E antibodies
The 667 mAb and serum anti-FrCas
E antibodies were assayed
as described previously [17,18]. The 667 and 678 mAbs were used
as standards for quantifications of anti-FrCas
E IgG2a and IgG1
antibodies, respectively.
Spleen infectious center (SIC) assays
Serial dilutions of single-cell suspensions from FrCas
E-infected
mouse spleens prepared as in ref. [22] were plated on 25%
confluent indicator Mus dunni cell cultures. After 3 days of co-
culture, ffu were score by FIA [see 18,62]
Stimulation of memory CTL responses
Mice were injected i.v. with 0.6610
6 FrCas
E-infected spleno-
cytes resuspended in 100 ml of PBS.
Assay of CD8
+ T cells specific for FrCas
E-infected cells by
flow cytometry
5610
5 splenocytes were stained with both an anti-CD8-APC-
(Becton Dickinson) and a PE-labeled MHC class I H-2D
b tetramer
(Beckman Coulter) specific for the Friend Virus GagL peptide (D
b-
GagL tetramers) [32,63] for 15 min at room temperature in PBA
(PBS containing 2% FCS and 0.01% sodium azide). Cells were
analyzed by flow cytometry after paraformaldehyde fixation.
Alternatively, CD3
+ cells were isolated from spleen by a negative
selection kit (Invitrogen Dynal) and stained with the D
b-GagL
tetramers and anti-CD8, anti-CD62L (Becton Dickinson), anti-
CD44, anti-CD127 and anti-CD25 mAbs (eBioscience) and analyzed
by flow cytometry. IFN-c production in CD3
+ cells cultured in the
presence of PMA-ionomycin and brefeldin A was measured by using
the intracellular staining kit (Cytofix/Cytoperm Fixation/Permeabi-
lization, Becton Dickinson) according to the supplier’s protocol.
In vivo cytotoxicity assays
Experiments were conducted as described in [22]. Briefly, red
blood cell-free splenocytes from naive mice were either pulsed with
the GagL peptide [33] or kept unloaded to use them as control
splenocytes for quantification of spontaneous cell death in adoptive
transfer experiments. GagL-loaded- and control splenocytes were
labelled by incubation in either 5 mM CFSE (CFSE
high cells)- or
0.5 mM CFSE (CFSE
low cells)-containing PBS, respectively.
Labeled cells were mixed in a 1:1 ratio and 10
7 cells of the mix
were injected i.v. in each recipient 8 days after viral challenge.
16 hours later, mice were sacrificed for flow cytometry quantifi-
cation of splenic CFSE
low- and CFSE
high cells. The CTL activity
against GagL-loaded splenocytes was calculated from the ratio of
CFSE
high/CFSE
low cells.
Preparation and characterization of BMDCs and
phenotyping of retroviral expression in BMDCs and
spleen DCs
Functional studies were performed with DCs obtained from
bone marrow precursors as described in ref. [64]. B- and T
lymphocytes and macrophages were eliminated from bone
marrow cells, which were cultured at 37uC for 7 days in 5%
FCS-containing RPMI medium complemented with GM-CSF
and IL-4 (200 U/ml each), 2 mM glutamine, 1% non-essential
amino acids, 50 mM b-mercapto-ethanol and 1 mM sodium
pyruvate in the presence of 5% CO2. At that time, they were
used as immature DCs referred here to as BMDCs. They were 80–
90% pure, as assayed by flow cytometry for cells doubly positive
for MHC class II and CD11c. BMDC activation was assessed by
flow cytometry using mAbs directed to MHC-II (eBioscience),
CD11c, CD40, and CD86 (Becton Dickinson) after 24 h of
stimulation by SpFr, SpFr-IC or LPS (InVivoGen; 1 mg/ml).
Retroviral Env expression on MHC-II
+CD11c
+ BMDCs, as well
as on control Mus dunni cells, was also assayed by flow cytometry
using the FITC-labeled 667 mAb after 48 hours of co-culture with
SpFr or SpFr-IC. Co-expression of Env, CD11c and MHC-II on
splenic DCs was assessed by flow cytometry 8, 15 and 35 post-
infection after preparation of splenocytes from sacrificed mice.
Assay of CD8
+ T cells priming activity
ICs were formed by incubating 5610
4 FrCas
E-infected
splenocytes (SpFr) with either (i) 10 mg of the purified 667 mAb
(SpFr-IC) or (ii) 15 mg of the 667 F(ab’)2 fragment (SpFr- F(ab’)2)
or (iii) sera containing anti-FrCas
E antibodies (SpFr-serum). Non-
immune sera were taken as controls in the latter case. 5610
5
BMDCs were co-cultured overnight with SpFr or SpFr-IC in the
presence or in the absence of the 2.4G2 FccR-blocking mAb, or
with SpFr-F(ab’)2 or SpFr-serum. After 2 washes in PBS, DCs
were cultured with CD8
+ T cells purified from lymph nodes of
GagL-TCR-TG transgenic mice [34] (60% of CD8
+ cells, of
which 98% expressed the GagL-specific TCR, and labeled in the
presence of 5 mM CFSE). Cell proliferation was followed up by
flow cytometry analysis of CFSE- and CD8-positive cells 5 days
later. Non-infected splenocytes were used as controls in these
experiments. For in vivo experiments, 2610
5 or 2610
6 FrCas
E-
infected splenocytes (SpFr) were incubated or not with 150 mgo f
the purified 667 mAb and administered i.v. into naive mice to
assess GagL-specific CD8
+ T-cell expansion potential and
cytotoxic activity as described above.
Assay of in vivo anti-FrCas
E antibody cytolysis activity
The assay used is derived from ref. [65]. Non-infected and
FrCas
E-infected splenocytes were labeled with 0.5 mM (Sp
CFSE
low) and 5 mM (SpFr CFSE
high) CSFE, respectively. They
were then mixed in a 1:1 ratio and administered i.v. to mice,
which, afterwards, received either 200 mg of 667 or pools of sera
containing anti-FrCas
E antibodies by i.p. administration. Alterna-
tively, a mixture of non-infected and FrCas
E-infected splenocytes
at 1:1 ratio was pre-incubated with either 667 or a pool of sera
containing anti-FrCas
E antibodies from infected/treated mice
prior to i.v. administration. The ratio of CFSE
low/CFSE
high cells
was assayed by flow cytometry 5 and 24 hours later, respectively.
To assess the contribution of NK cells to antibody-mediated
cytolysis, 50 ml of the anti-asialo GM1 anti-NK antibody was
administrated i.v. to mice on days 6, 3 and 1 prior to cytolysis
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factor (Quiadel) were administrated i.p. 1 day prior to cytolysis
assay and 20 units the same day of the assay, respectively.
Uptake of SpFr and SpFr-IC by DCs
SpFr were stained with the red-fluorescing dye PKH26 (Sigma)
[66] at a concentration of 2 mg/ml for 5 min and half of the
preparation was used to form SpFr-IC. Fluorescent SpFr and
SpFr-IC were then placed in the presence of DCs at a 1:1 ratio for
various periods of time at either 37uC, to measure uptake, or 0uC,
to measure simple binding. Uptake was quantified by flow
cytometry after subtraction of simple binding signals.
Statistics
Data are presented as mean 6 SEM. Statistical significance
between the groups was determined by applying either the
Student’s t test, when two groups were compared, or a non-
parametric one-way ANOVA test with Dunn’s multiple compar-
ison post-test when three groups were compared. A P value lower
than 0,05 was considered as statistically significant.
Supporting Information
Figure S1 A short 667 mAb treatment prevents mice from
developing leukemia. Three groups of 8 day-old mice were
infected with FrCas
E. One group was treated with 667 (infected/
treated) 1 hour post-infection and on days 2 and 5 post-infection, a
second group was treated with a control non-neutralizing mAb of
the same isotype (anti-b-2,6-fructosan IgG2a mAb from Sigma;
infected/control mAb-treated), and the third group was not
treated (infected/non-treated). A fourth group of mice, not
infected but treated with 667, was taken as control (non-
infected/treated). (A) Survival of mice. (B) Hematocrits. The presented
data are the average of values obtained from at least 10 animals
per time point. Error bars indicate SEM. Lines indicate linear
regressions. For the sake of clarity, the percentage of hematocrit of
infected/control mAb-treated mice and that of non-infected/
treated mice was not shown but they were comparable to that of
infected/non-treated and infected-treated, respectively. (C) Spleen
weights. Infected/control mAb-treated- and infected/non-treated
mice showed comparable spleen swelling (not shown). Bars
indicate mean values. Data presented are the compilation of
results from 3 independent experiments: (infected/treated mice,
n=29; infected/non-treated, n=25 mice; non-infected/treated
mice, n=15; infected/control mAb-treated, n=4 mice).
Found at: doi:10.1371/journal.ppat.1000948.s001 (0.37 MB TIF)
Figure S2 Characterization of the humoral response developing
in infected/treated mice (complement to Figure 1). (A) anti-FrCas
E
IgG2a and IgG1 responses. Anti-FrCas
E IgG2as and IgG1s contained
in the sera of mice analyzed in Figure 1C were assayed by ELISA.
One of 2 independent experiments with similar outcomes is
presented. The data are the average of values obtained from at
least 10 animals per time point. Non-infected/treated mice were
negative for anti-FrCas
E IgGs and are not presented. Error bars
indicate SEM. (B) Neutralization activity. Mice were infected as
described in Figure 1. Neutralization activity was assayed by FIA
in the presence of the indicated serum dilutions of pooled sera from
at least 4 mice per time point and per condition. The values are the
average of the results obtained in 2 independent experiments.
Found at: doi:10.1371/journal.ppat.1000948.s002 (0.35 MB TIF)
Figure S3 Phenotypic characterization of CD8
+ T-cell responses
in infected/treated animals (complement to Figure 2). Mice were
infected and treated as in Figure 1. CD3
+ cells were isolated by
negative selection from spleens of 2 age-matched non-infected/
non-treated mice and 3 infected/treated mice on day 56 post-
infection. CD3
+ cells were then stained with the D
b-GagL
tetramer and anti-CD8- and anti-CD127 mAbs for flow cytometry
analysis. Data from 1 age-matched non-infected/non-treated mice
and 3 infected/treated mice are presented. These data, together
with the results presented in Figure 2, show that infected/treated
mice generate a substantial CD8
+ T-cell memory pool mainly
composed of effector-memory cells.
Found at: doi:10.1371/journal.ppat.1000948.s003 (0.18 MB TIF)
Figure S4 Statistical analysis of the data presented in Figure 4B.
The proliferation of CFSE-labeled GagL-TCR-TG CD8
+ T cells
was measured in each assay by quantifying the percentage of cells
with decreased CFSE fluorescence (CFSE staining is divided by
two at each cell division). The data from 3 independent
experiments were statistically analyzed using the Student’s t test
(*P=0,003).
Found at: doi:10.1371/journal.ppat.1000948.s004 (0.17 MB TIF)
Figure S5 (complement to Figure 5). In vivo enhancement of the
anti-FrCas
E CD8
+ T-cell response by cellular ICs. SpFr, or SpFr-
IC, were administered i.v. to non-infected/non-treated mice. Two
groups of mice (n=3) were used. In one of them, 2610
6 FrCas
E-
infected splenocytes (SpFr) were i.v. injected in the absence of 667
whereas, in the other group, the same amount of FrCas
E-infected
splenocytes was used after immune complex formation with
150 mg of 667 (SpFr-IC). Nine days later, both the expansion of
GagL-specific CD8
+ T cells and CTL activity were assessed in vivo
as described in Figure 3. Non-infected/non-treated mice with no
further treatment (NI/NT) were used as controls (A). Proliferation of
GagL-specific CD8
+ T cells. The data obtained with the 3 mice
receiving either SpFr or SpFr-IC mouse are presented together
with 1 control mouse. (B) CTL activity against GagL-loaded splenocytes.
The data obtained with the 3 mice receiving either SpFr or SpFr-
IC are presented together with 1 control mouse.
Found at: doi:10.1371/journal.ppat.1000948.s005 (0.59 MB TIF)
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